Table 2.
Correlations between Her2/Her3 Expression and Clinicopathological Parameters
| Her2 (membranous staining) | Her3 (membranous staining) | Her3 (cytoplasmic staining) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Negative (%) | Positive (%) | P | Negative (%) | Positive (%) | P | Negative (%) | Positive (%) | P | |
| Primary tumors | 283 (73.1) | 104 (26.9) | 353 (91.2) | 34 (8.8) | 87 (22.5) | 300 (77.5) | |||
| Age | |||||||||
| Median | 61.0 | 61.0 | 0.866 | 60.0 | 63.1 | 0.140 | 61 | 61 | 0.972 |
| Range | 23 - 88 | 20 - 95 | 20 - 95 | 41 - 81 | 24 - 95 | 20 - 88 | |||
| Gender | |||||||||
| Male | 217 (74.3) | 75 (25.7) | 0.355 | 271 (92.8) | 21 (7.2) | 0.052 | 66 (22.3) | 227 (77.7) | 0.856 |
| Female | 66 (69.5) | 29 (30.5) | 82 (86.3) | 13 (13.7) | 22 (23.2) | 73 (76.8) | |||
| Primary tumor sites | |||||||||
| Larynx | 137 (74.9) | 46 (25.1) | 0.557 | 164 (89.6) | 19 (10.4) | 0.345 | 39 (21.3) | 144 (78.7) | 0.541 |
| Oral cavity | 116 (73.9) | 41 (26.1) | 147 (93.6) | 10 (6.4) | 36 (22.9) | 121 (77.1) | |||
| Pharynx | 14 (60.9) | 9 (39.1) | 21 (91.3) | 2 (8.7) | 8 (34.8) | 15 (65.2) | |||
| Nasal cavity | 10 (62.5) | 6 (37.5) | 13 (81.3) | 3 (18.7) | 2 (12.5) | 14 (87.5) | |||
| Salivary gland | 6 (75.0) | 2 (25.0) | 8 (100) | 0 (0.0) | 2 (25.0) | 6 (75.0) | |||
| Histological grading1 | |||||||||
| Grade 1 | 71 (79.8) | 18 (20.2) | 0.021 | 85 (95.5) | 4 (4.5) | 0.150 | 24 (27.0) | 65 (73.0) | 0.244 |
| Grade 2 | 157 (68.3) | 73 (31.7) | 208 (90.4) | 22 (9.6) | 54 (23.5) | 176 (76.5) | |||
| Grade 3 | 49 (83.1) | 10 (16.9) | 51 (86.4) | 8 (13.6) | 9 (15.3) | 50 (84.7) | |||
| Lymph node metastasis2 | |||||||||
| No | 265 (73.0) | 98 (27.0) | 0.343 | 331 (91.2) | 32 (8.8) | 0.430 | 82 (22.6) | 281 (77.4) | 0.295 |
| Yes | 13 (81.2) | 3 (18.8) | 14 (87.5) | 2 (12.5) | 5 (31.2) | 11 (68.8) | |||
1Histological grading data were available for 378 cases (97.7%).
2Lymph node metastases data were available for 379 cases (97.9%).